Sunday 18 October 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.26
0.06
−1.81%
Follow PRLD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (57.73%) | (95.25%) | (99.45%) | (103.99%) |
+8 more TTM periods Free account |
|
| (39.76%) | (59.64%) | (62.81%) | (76.56%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (2,115.06%) | |
Return on Tangible Assets |
(49.89%) | (163.46%) | (172.11%) | (244.73%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.34) | (0.53) | (0.73) | (1.32) | |
Free Cash Flow |
(33.25) | (43.76) | (56.37) | (100.28) | |
Capital Expenditures |
— | — | (0.07) | (0.12) | |
| Other line items | |||||
Cash ROIC |
(11.65%) | (30.87%) | (32.80%) | (88.36%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
309.63% | 381.68% | 492.69% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
90.92% | 105.08% | 117.06% | 0.00% | |
Share Based Compensation of Revenue |
36.99% | 48.65% | 62.24% | 0.00% | |
Operating CF/Net income |
0.55 | 0.56 | 0.57 | 0.90 | |
Depreciation/Fixed assets |
0.15 | 0.18 | 0.26 | 0.12 | |
Capex/Depreciation |
0.00 | 0.00 | (0.05) | (0.19) | |
Revenue per Share |
0.23 | 0.25 | 0.25 | 0.00 | |
Operating CF per Share |
(0.34) | (0.53) | (0.73) | (1.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates